期刊文献+

高效液相色谱法同时测定人血浆中氯氮平、阿立哌唑浓度 被引量:15

原文传递
导出
摘要 目的:建立同时测定人血浆中氯氮平、阿立哌唑浓度的高效液相色谱法。方法:以DiamonsilTMC18(150mm×4.6mm,5μm)为色谱柱,流动相为30mmol·L-1醋酸铵-甲醇(23∶77);流速0.8mL.min-1;柱温40℃;检测波长254nm。以醋酸乙酯与二氯甲烷(80∶20)为提取剂。结果:氯氮平在20.0~1280.0μg·L-1、阿立哌唑在25.0~1600.0μg.L-1范围内,峰面积与其浓度呈良好线性关系;氯氮平、阿立哌唑的高、中、低3种浓度相对平均回收率分别为99.53%,98.47%,100.15%和98.86%,97.25%,101.16%,提取回收率分别为79.25%,77.31%,74.28%和80.63%,78.51%,73.02%;日内、日间RSD均低于9%(n=5)。分析方法的检测限为10.0μg·L-1;氯氮平线性方程:Y=1.526X+1.73,r=0.9991(n=7);阿立哌唑线性方程:Y=0.689X-2.12,r=0.9994(n=7)。结论:该方法灵敏、准确、简单、快速,可用于临床血药浓度监测和药动学研究。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2010年第15期1339-1340,共2页 Chinese Journal of Hospital Pharmacy
基金 广东省自然科学基金资助项目(编号:8151037001000001)
  • 相关文献

参考文献7

  • 1张璞,李中东,焦正.第二代非典型抗精神病药——阿立哌唑[J].中国药学杂志,2005,40(3):238-240. 被引量:59
  • 2孙爱风,吴范宏.阿立哌唑[J].中国新药杂志,2003,12(7):571-571. 被引量:10
  • 3Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability,and safety of aripiprazole following multiple oral dosing in normal healthy volunteers[J]. J Clin Pharmacol, 2004, 44(2):179-87.
  • 4Shimokawa Y,Akiyama H, Kashiyama E, et al. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2005,821 (1) : 8-14.
  • 5吴岚,朱军,刘文宪,刘伟忠,王华成.高效液相色谱法测定人血浆中氯氮平浓度[J].医药导报,2008,27(4):386-388. 被引量:9
  • 6Mercolini I., Bugamelli F, Kenndler. Simultaneous determination of the antipsychotic drugs levomepromazine and elozapine and their main metabolites in human plasma by a HPLC-UV method with solid-phase extraction[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2006,542( 1 ) : 237-43.
  • 7Niederlander HA, Koster EH, Hilhorst MJ. High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on line coupling of solid phase extraction with liquid chromatography mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 20(16,834 ( 1-2 ) : 98-107.

二级参考文献16

  • 1邓世平,刘小花,邹晓华,潘大津,徐哲明.氯氮平联合肌苷口服液治疗难治性精神分裂症30例[J].医药导报,2006,25(8):789-791. 被引量:3
  • 2司天梅,舒良.氯氮平的药代动力学及血药浓度与临床疗效的关系[J].中国临床药理学杂志,1996,12(3):178-183. 被引量:17
  • 3Butini S, Campiani G, Angelis MD, et al. Novel antipsychotic agents:recent advances in the drug treatment of schizophrenia [J].Expert Opinion on Therapeutic Patents, 2003, 13(4): 425.
  • 4Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials [J]. Schizophr Res, 2003, 61 (2~3):123.
  • 5Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug[J]. Ann Pharmacother, 2003, 37(5): 687.
  • 6Bristol-Myers Squibb Company. ABILIFY (aripiprazole) Tablets[EB/OL]. http://www.bms.com/cgi-bin/anybin.pl? sql = select%20PPI% 20from% 20TB_PRODUCT_PPI% 20where% 20PPI_SEQ =101&key = PPI, 2002-11-15/2003-07-17.
  • 7Keck Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic[J]. Expert Opin Investig Drugs, 2003, 12 (4):655.
  • 8Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety [J]. Expert Opin Pharmacother, 2002, 3(12): 1773.
  • 9Marcus R, Gharbia NA, Kujawa MJ, et al. Aripiprazole for longterm maintenance treatment of schizophrenia [A]. The 2002 annual meeting of the American College of Clinical Pharmacy [C], Albuquerque, New Mexico, Sage Science press, October 20~ 23, 2002.
  • 10Carson W, Pigott T, Saha A, et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia [A] . The 42nd annual meeting of the New Clinical Drug Evaluation Unit[C], Boca Raton,Florida, The National Institute of Mental Health,June 10 ~ 13, 2002.

共引文献74

同被引文献108

引证文献15

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部